Dr. Uzzo on Trials Investigating Immunotherapy in Kidney Cancer

Robert G. Uzzo, MD
Published: Wednesday, Jun 21, 2017



Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice-president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses trials investigating immunotherapy in kidney cancer.

There are ongoing trials investigating immunotherapy regimens in patients with kidney cancer. The PROSPER trial is investigating a neoadjuvant therapy followed by an adjuvant therapy, whereas a different trial is only investigating adjuvant therapy, states Uzzo.

Currently, there is not a lot of adjuvant therapy being given in the kidney cancer space, which might affect how the trials accrue patients, explains Uzzo.



Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice-president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses trials investigating immunotherapy in kidney cancer.

There are ongoing trials investigating immunotherapy regimens in patients with kidney cancer. The PROSPER trial is investigating a neoadjuvant therapy followed by an adjuvant therapy, whereas a different trial is only investigating adjuvant therapy, states Uzzo.

Currently, there is not a lot of adjuvant therapy being given in the kidney cancer space, which might affect how the trials accrue patients, explains Uzzo.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x